Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Germ Cell and Embryonal » Neuroectodermal Tumors » Neoplasms, Neuroepithelial » Glioma » Astrocytoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Neoplasms, Neuroepithelial » Glioma » Astrocytoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Nerve Tissue » Neuroectodermal Tumors » Neoplasms, Neuroepithelial » Glioma » Astrocytoma
Description
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082) MeSH
Hierarchy View
Subtype Terms (1)
Glioblastoma
650 drugs (222 approved, 428 experimental)
Approved Indicated Drugs (4)
Phase 4 Indicated Drugs (2)
Phase 3 Indicated Drugs (15)
Phase 2 Indicated Drugs (55)
Phase 1 Indicated Drugs (87)
autologous dendritic cells loaded with autologous tumor lysate
azurin-derived cell-penetrating peptide p28
carboxylesterase-expressing allogeneic neural stem cells
carcinoembryonic antigen-expressing measles virus
Other Experimental Indicated Drugs (16)
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (39)
Chinese Academy of Medical Sciences
Colombian foundation center for epilepsy and neurological disease
Colombian Foundation for Epilepsy and Neurological Disease
Eastern Cooperative Oncology Group
Mashhad University of Medical Sciences
National Cancer Institute (NCI)
Neuro-Oncology Working Group of the German Cancer Society
Organization Involved with Phase 2 Indications (78)
Feinstein Institute for Medical Research
Herbert Irving Comprehensive Cancer Center
Medical University of South Carolina
Methodist Cancer Center, Houston, Texas
National Comprehensive Cancer Network
National Institutes of Health (NIH)
Pediatric Brain Tumor Consortium
Pediatric Oncology Experimental Therapeutics Investigation Consortium
Organization Involved with Phase 1 Indications (57)
American Lebanese Syrian Associated Charities
Cancer and Leukemia Group B (CALGB)
Cannonball Kids' Cancer Foundation
European Organisation for Research and Treatment of Cancer
Garnett McKeen Laboratory Inc.
Institut de Cancerologie de l'Ouest Paul Papin
State University of New York, Buffalo
The Andrew McDonough B+ Foundation
Organization Involved with Other Experimental Indications (8)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
